News and Announcements
Prescient Therapeutics Secures $7.0M Capital Raising
- Published May 18, 2016 4:26PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
18th May 2016, ASX Announcement
- $7.0 M institutional placement
- Rights issue on same terms to raise up to a further $3.4 M
Prescient Therapeutics Limited (ASX: PTX), a clinical stage oncology company, is pleased to advise the successful completion of of an institutional placement to raise $7.0 million.
The placement, largely to life-science focused Australian institutional investors, has been undertaken which will involve the issue of approximately 77.7 million shares at 9.0 cents per share with 1 attaching option for every 2 shares subscribed (exercisable at 18 cents; expiring 30 June 2018). The placement will be undertaken in two tranches. The first tranche of approximately 19.4 million shares will be unconditional, with shareholders to approve the second tranche (of approximately 58.3 million) and all attaching options.
To view the full announcement, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
